Sarah L Kerns

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5507724/publications.pdf

Version: 2024-02-01

56	3,105	230014	206121
papers	citations	27 h-index	51 g-index

58	58	58	5304
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Relationships between cytokines and cognitive function from pre- to post-chemotherapy in patients with breast cancer. Journal of Neuroimmunology, 2022, 362, 577769.	1.1	7
2	Use of angiotensin converting enzyme inhibitors is associated with reduced risk of late bladder toxicity following radiotherapy for prostate cancer. Radiotherapy and Oncology, 2022, 168, 75-82.	0.3	10
3	A genome-wide association study of radiotherapy induced toxicity in head and neck cancer patients identifies a susceptibility locus associated with mucositis. British Journal of Cancer, 2022, 126, 1082-1090.	2.9	12
4	Overview of health-related quality of life and toxicity of non-small cell lung cancer patients receiving curative-intent radiotherapy in a real-life setting (the REQUITE study). Lung Cancer, 2022, 166, 228-241.	0.9	5
5	Exploratory Analysis of Associations Between Whole Blood Mitochondrial Gene Expression and Cancer-Related Fatigue Among Breast Cancer Survivors. Nursing Research, 2022, Publish Ahead of Print, .	0.8	2
6	Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. Nature Genetics, 2021, 53, 65-75.	9.4	264
7	Development of a method for generating SNP interaction-aware polygenic risk scores for radiotherapy toxicity. Radiotherapy and Oncology, 2021, 159, 241-248.	0.3	11
8	Radiogenomics Consortium Genome-Wide Association Study Meta-Analysis of Late Toxicity After Prostate Cancer Radiotherapy. Journal of the National Cancer Institute, 2020, 112, 179-190.	3.0	71
9	A Deep Learning Approach Validates Genetic Risk Factors for Late Toxicity After Prostate Cancer Radiotherapy in a REQUITE Multi-National Cohort. Frontiers in Oncology, 2020, 10, 541281.	1.3	15
10	Relationship of Cisplatin-Related Adverse Health Outcomes With Disability and Unemployment Among Testicular Cancer Survivors. JNCI Cancer Spectrum, 2020, 4, pkaa022.	1.4	11
11	Genomics models in radiotherapy: From mechanistic to machine learning. Medical Physics, 2020, 47, e203-e217.	1.6	17
12	Oncology Scan: Radiation Biology and Genomic Predictors of Response. International Journal of Radiation Oncology Biology Physics, 2020, 107, 393-397.	0.4	0
13	Survey of Radiation Oncologists to Assess Interest and Potential Use of a Genetic Test Predicting Susceptibility for the Development of Toxicities After Prostate Cancer Radiation Therapy. Advances in Radiation Oncology, 2020, 5, 897-904.	0.6	1
14	The Implications of Genetic Testing on Radiation Therapy Decisions: A Guide for Radiation Oncologists. International Journal of Radiation Oncology Biology Physics, 2019, 105, 698-712.	0.4	69
15	Multicenter Randomized Controlled Trial of Omega-3 Fatty Acids Versus Omega-6 Fatty Acids for the Control of Cancer-Related Fatigue Among Breast Cancer Survivors. JNCI Cancer Spectrum, 2019, 3, pkz005.	1.4	26
16	Impact of chemotherapy for breast cancer on leukocyte DNA methylation landscape and cognitive function: a prospective study. Clinical Epigenetics, 2019, 11, 45.	1.8	36
17	Impact of cisplatin-related adverse health outcomes (AHOs) on employment outcomes and self-reported health (SRH) among testicular cancer survivors (TCS).. Journal of Clinical Oncology, 2019, 37, e16058-e16058.	0.8	0
18	Machine Learning on a Genome-wide Association Study to Predict Late Genitourinary Toxicity After Prostate Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2018, 101, 128-135.	0.4	73

#	Article	IF	Citations
19	Role of Germline Genetics in Identifying Survivors at Risk for Adverse Effects of Cancer Treatment. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 775-786.	1.8	12
20	Cumulative Burden of Morbidity Among Testicular Cancer Survivors After Standard Cisplatin-Based Chemotherapy: A Multi-Institutional Study. Journal of Clinical Oncology, 2018, 36, 1505-1512.	0.8	95
21	Machine Learning and Radiogenomics: Lessons Learned and Future Directions. Frontiers in Oncology, 2018, 8, 228.	1.3	54
22	Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nature Genetics, 2018, 50, 928-936.	9.4	652
23	Radiation biology and oncology in the genomic era. British Journal of Radiology, 2018, 91, 20170949.	1.0	25
24	Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. Nature Communications, 2018, 9, 2256.	5.8	88
25	Meeting requirements for survivorship visits: Interventions for patient identification.. Journal of Clinical Oncology, 2018, 36, 59-59.	0.8	0
26	Computational methods using genome-wide association studies to predict radiotherapy complications and to identify correlative molecular processes. Scientific Reports, 2017, 7, 43381.	1.6	35
27	Preconditioned Random Forest Regression. , 2017, , .		0
28	Data-Based Radiation Oncology: Design of Clinical Trials in the Toxicity Biomarkers Era. Frontiers in Oncology, 2017, 7, 83.	1.3	36
29	Multi-Institutional Assessment of Adverse Health Outcomes Among North American Testicular Cancer Survivors After Modern Cisplatin-Based Chemotherapy. Journal of Clinical Oncology, 2017, 35, 1211-1222.	0.8	86
30	Clinical, sociodemographic, and behavioral factors associated with cumulative burden of morbidity (CBM) among testicular cancer survivors (TCS) in the Platinum study.. Journal of Clinical Oncology, 2017, 35, 10075-10075.	0.8	1
31	A phase II RCT of high-dose vitamin D supplementation for androgen deprivation therapy (ADT)-induced bone loss among older prostate cancer (PCa) patients.. Journal of Clinical Oncology, 2017, 35, 10113-10113.	0.8	1
32	An integrative approach to personalized cancer survivorship care at an academic medical center.. Journal of Clinical Oncology, 2017, 35, 37-37.	0.8	0
33	TNFSF10/TRAIL regulates human T4 effector memory lymphocyte radiosensitivity and predicts radiation-induced acute and subacute dermatitis. Oncotarget, 2016, 7, 21416-21427.	0.8	16
34	Comprehensive Audiometric Analysis of Hearing Impairment and Tinnitus After Cisplatin-Based Chemotherapy in Survivors of Adult-Onset Cancer. Journal of Clinical Oncology, 2016, 34, 2712-2720.	0.8	197
35	Optimal design and patient selection for interventional trials using radiogenomic biomarkers: A REQUITE and Radiogenomics consortium statement. Radiotherapy and Oncology, 2016, 121, 440-446.	0.3	15
36	Radiogenomics: A systems biology approach to understanding genetic risk factors for radiotherapy toxicity?. Cancer Letters, 2016, 382, 95-109.	3.2	68

#	Article	IF	Citations
37	Meta-analysis of Genome Wide Association Studies Identifies Genetic Markers of Late Toxicity Following Radiotherapy for Prostate Cancer. EBioMedicine, 2016, 10, 150-163.	2.7	69
38	Individual patient data meta-analysis shows a significant association between the ATM rs1801516 SNP and toxicity after radiotherapy in 5456 breast and prostate cancer patients. Radiotherapy and Oncology, 2016, 121, 431-439.	0.3	98
39	How Will Big Data Improve Clinical and Basic Research in Radiation Therapy?. International Journal of Radiation Oncology Biology Physics, 2016, 95, 895-904.	0.4	25
40	The use of isodose levels to interpret radiation induced lung injury: a quantitative analysis of computed tomography changes. Quantitative Imaging in Medicine and Surgery, 2016, 6, 35-41.	1.1	8
41	Cardiovascular disease (CVD) risk factors and health behaviors following cisplatin-based chemotherapy (CHEM): A multi-institutional study of testicular cancer survivors (TCS).. Journal of Clinical Oncology, 2016, 34, 129-129.	0.8	1
42	Cardiovascular disease (CVD) risk factors and health behaviors after cisplatin-based chemotherapy (CHEM): A multi-institutional study of testicular cancer survivors (TCS) in the Platinum study.. Journal of Clinical Oncology, 2016, 34, 10087-10087.	0.8	0
43	Cumulative burden of morbidity (CBM) among testicular cancer survivors (TCS) in the Platinum study.. Journal of Clinical Oncology, 2016, 34, 10089-10089.	0.8	0
44	Lhermitteâ€™s Sign following VMAT-Based Head and Neck Radiation-Insights into Mechanism. PLoS ONE, 2015, 10, e0139448.	1.1	6
45	The Prediction of Radiotherapy Toxicity Using Single Nucleotide Polymorphismâ^'Based Models: A Step Toward Prevention. Seminars in Radiation Oncology, 2015, 25, 281-291.	1.0	52
46	XRCC1 Polymorphism Associated With Late Toxicity After Radiation Therapy in Breast Cancer Patients. International Journal of Radiation Oncology Biology Physics, 2015, 92, 1084-1092.	0.4	64
47	Radiogenomics: the search for genetic predictors of radiotherapy response. Future Oncology, 2014, 10, 2391-2406.	1.1	63
48	STROGAR â€“ STrengthening the Reporting Of Genetic Association studies in Radiogenomics. Radiotherapy and Oncology, 2014, 110, 182-188.	0.3	59
49	Radiogenomics: Using Genetics to Identify Cancer Patients at Risk for Development of Adverse Effects Following Radiotherapy. Cancer Discovery, 2014, 4, 155-165.	7.7	103
50	A three-stage genome-wide association study identifies a susceptibility locus for late radiotherapy toxicity at 2q24.1. Nature Genetics, 2014, 46, 891-894.	9.4	114
51	Radiogenomics: Radiobiology Enters the Era of Big Data and Team Science. International Journal of Radiation Oncology Biology Physics, 2014, 89, 709-713.	0.4	99
52	A genome wide association study (GWAS) providing evidence of an association between common genetic variants and late radiotherapy toxicity. Radiotherapy and Oncology, 2014, 111, 178-185.	0.3	128
53	A 2-Stage Genome-Wide Association Study to Identify Single Nucleotide Polymorphisms Associated with Development of Urinary Symptoms After Radiotherapy for Prostate Cancer. Journal of Urology, 2013, 190, 102-108.	0.2	55
54	A 2-Stage Genome-Wide Association Study to Identify Single Nucleotide Polymorphisms Associated With Development of Erectile Dysfunction Following Radiation Therapy for Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2013, 85, e21-e28.	0.4	59

#	Article	IF	Citations
55	Genome-wide association study identifies a region on chromosome 11q14.3 associated with late rectal bleeding following radiation therapy for prostate cancer. Radiotherapy and Oncology, 2013, 107, 372-376.	0.3	70
56	Genetic Predictors of Cervical Dysplasia in African American HIV-Infected Women: ACTG DACS 268. HIV Clinical Trials, 2013, 14, 292-302.	2.0	1